The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Daewoong delivered KRW 1.055 trillion in sales, KRW 95.5 billion in operating profit and KRW 40.5 billion in net profit.
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
Subscribe To Our Newsletter & Stay Updated
